...esto, lo que, a decir de un experto, deja “cada vez más claro que el poscovid o la covid prolongada tiene una firma metabólica marcada por desórdenes en la maquinaria metabólica”. Reporta @PamBelluckhttps://t.co/1tKPZFlX7x
The new Alzheimer’s drug should only be used for a much narrower group of patients than the F.D.A.’s label allows, experts said. Even a strong supporter of approval said “there’s no evidence that it could be beneficial for any other stage of Alzheimer’s.” https://t.co/sp65vv5Lp7
Still, it seems to be the largest so far looking at post-Covid health issues. It underscores, says @zalaly, that "people with long Covid need multidisciplinary care and our health systems should adapt to this reality and develop capacity to deal with these patients."3/3
The study has limitations, including: it only uses private health insurance records, no control group to allow comparison to people who didn't have Covid, no data on when symptoms arose or how long problems persisted, diagnostic codes can miss or miscategorize symptoms. 2/3
Large new study on post-Covid health: 23 percent of nearly 2 million coronavirus patients sought medical care for new health problems one month or more after getting Covid-19. 1/3 https://t.co/5MOAR0A0Bf
This week, the FDA approved the new Alzheimer's drug aducanumab, but it’s unclear if the costly treatment actually leads to improved cognition and memory in people with the disease.
@NYtimes's reporter @PamBelluck shares more on #SciFriLive📻.